Highlights Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Real-time Estimate Cboe BZX Other stock markets 19:58:21 21/05/2024 BST			5-day change	1st Jan Change
1.41 ^USD	-5.97%		-2.78%	-24.73%

04-22	Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	MT
04-12	Top Premarket Decliners	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	04-22	MT
Top Premarket Decliners	04-12	MT
Top Midday Gainers	04-10	MT
Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder	04-10	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Adial Pharmaceuticals Receives New Patent Notice of Allowance from the United States Patent and Trademark Office	02-13	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence	19/10/23	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Adial Pharmaceuticals Granted Meeting With FDA for Alcohol Use Disorder Treatment Candidate; Shares Rise	07/03/23	MT
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder	06/03/23	CI
Adial Pharmaceuticals, Inc. Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder	21/02/23	CI
Adial Signs Option Deal for Sale of Purnovate to Company Led by Ex-CEO; Adial Shares Rise	01/02/23	MT
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Adial Pharmaceuticals, Inc. Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder	20/07/22	CI
Adial Pharmaceuticals Locks Database for Late-Stage Alcohol Use Disorder Trial, Sees Topline Results in July	27/06/22	MT
Adial Pharmaceuticals Announces Database Lock for the ONWARD(TM) Phase 3 Clinical Trial	27/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Highlights

Filters